The FDA clearance for Cumberland Pharmaceuticals' IND application is a significant milestone for the company, as it allows them to proceed with clinical trials for their Phase II study. This news is likely to have a positive impact on the company's stock price in the short term, as it demonstrates progress in their drug development pipeline and increases the potential for future revenue from the successful development and commercialization of the drug.